极低危前列腺癌分类在现代背景下相关性有限:来自大型机构主动监测队列的结果
该研究基于2000至2020年诊断的1276例主动监测患者,发现符合NCCN极低危(VLR)标准的患者近年显著减少,2018年后无患者符合VLR标准;而CAPRA评分能有效区分患者,并预测重复活检升级至Gleason分级分组≥2(HR 1.21,95%CI 1.05-1.39;p<0.01)。作者认为NCCN VLR标准在靶向活检时代适用性较低,CAPRA或类似工具是更好的当代风险分层工具。
要点
- 2000至2020年1276例主动监测患者中,符合NCCN极低危标准者近年显著减少,2018年后无患者符合。
- CAPRA评分可预测重复活检升级至Gleason分级分组≥2(HR 1.21,95%CI 1.05-1.39;p<0.01)。
- 作者认为NCCN极低危标准在靶向活检时代适用性较低,CAPRA或类似工具更适用于当代风险分层。
核心结论
- NCCN极低危标准在靶向活检时代适用性较低,CAPRA评分或类似工具是主动监测患者更好的当代风险分层工具。
研究设计与样本
- 大型机构主动监测队列,纳入2000至2020年诊断的患者(n=1276)。
主要发现
- 符合NCCN极低危标准的患者数近年显著减少,2018年后无患者符合VLR标准。
- CAPRA评分可预测重复活检升级至Gleason分级分组≥2(HR 1.21,95%CI 1.05-1.39;p<0.01),独立于年龄、基因组检测结果和磁共振成像 findings。
关键数值与推荐
- NCCN极低危分层基于阳性活检针数、每针肿瘤范围和前列腺特异性抗原密度。
- CAPRA评分预测重复活检升级至Gleason分级分组≥2的HR为1.21(95%CI 1.05-1.39;p<0.01)。
临床怎么用
- 作者认为NCCN极低危标准在靶向活检时代适用性较低,CAPRA评分或类似工具是更好的当代风险分层工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although the American Urological Association recently dropped the very low-risk (VLR) subcategory for low-risk prostate cancer (PCa) and the European Association of Urology does not substratify low-risk PCa, the National Comprehensive Cancer Network (NCCN) guidelines still maintain this stratum, which is based on the number of positive biopsy cores, tumor extent in each core, and prostate-specific antigen density. This subdivision may be less applicable in the modern era in which imaging-targeted prostate biopsies are common practice. In our large institutional active surveillance cohort of patients diagnosed from 2000 to 2020 (n = 1276), the number of patients meeting NCCN VLR criteria decreased significantly in recent years, with no patient meeting VLR criteria after 2018. By contrast, the multivariable Cancer of the Prostate Risk Assessment (CAPRA) score effectively substratified patients over the same period and was predictive of upgrading on repeat biopsy to Gleason grade group ≥2 on multivariable Cox proportional-hazards regression modeling (hazard ratio 1.21, 95% confidence interval 1.05-1.39; p < 0.01), independent of age, genomic test results, and magnetic resonance imaging findings. These findings suggest that the NCCN VLR criteria are less applicable in the targeted biopsy era, and that the CAPRA score or similar instruments are better contemporary risk stratification tools for men on active surveillance. PATIENT SUMMARY: We investigated whether the National Comprehensive Cancer Network classification of very low risk (VLR) for prostate cancer is relevant in the modern era. We found that in a large group of patients on active surveillance, no man diagnosed after 2018 satisfied the VLR criteria. However, the Cancer of the Prostate Risk Assessment (CAPRA) score discriminated patients by cancer risk at diagnosis and was predictive of outcomes on active surveillance, and thus may be a more relevant classification scheme in the modern era.
引用
- Shee K, Cowan JE, Balakrishnan A, et al. Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort. Eur Urol. 2023. PMID: 36870794. doi:10.1016/j.eururo.2023.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。